Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system - PubMed (original) (raw)
. 2007 Nov 1;45(9):1141-51.
doi: 10.1086/522187. Epub 2007 Sep 26.
Affiliations
- PMID: 17918075
- DOI: 10.1086/522187
Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system
Lynne V McFarland et al. Clin Infect Dis. 2007.
Abstract
Background: Prompted by the changing profile of Clostridium difficile infection and the impact of formulary policies in hospitals, we performed this study when an increase in the incidence of C. difficile-associated disease was noted at our health care center (Veterans Administration Puget Sound Health Care System, Seattle, Washington).
Methods: A retrospective, matched case-control study of patients presenting to the Veterans Administration Puget Sound Health Care System, Seattle, Washington during 2004 was performed. Conditional logistic analysis determined risk factors for case patients, defined as individuals with diarrhea and test results (i.e., culture or toxin assay results) positive for C. difficile, and control subjects, defined as individuals with diarrhea and test results negative for C. difficile.
Results: C. difficile-associated disease incidence was 29.2 cases per 10,000 inpatient-days. The increase in the incidence of C. difficile-associated diarrhea that paralleled increased gatifloxacin use was not attributable to use of the antimicrobial but was a reflection of seasonal variation in the rate of C. difficile-associated disease. Multivariate analysis controlling for the time at which the assay was performed, the age of the patient, ward, and source of acquisition (community-acquired vs. nosocomial disease) found 6 significant risk factors for C. difficile-associated diarrhea: receipt of clindamycin (adjusted odds ratio [aOR], 29.9; 95% confidence interval [CI], 3.58-249.4), receipt of penicillin (aOR, 4.1; 95% CI, 1.2-13.9), having a lower intestinal condition (aOR, 2.8; 95% CI, 1.3-6.1), total number of antibiotics received (aOR, 1.4; 95% CI, 1.1-1.7), number of prior hospital admissions (aOR, 1.3; 95% CI, 1.1-1.6), and number of comorbid conditions (aOR, 1.3; 95% CI, 1.1-1.5).
Conclusions: The increase in the number of cases of C. difficile-associated disease was not attributable to a formulary change of fluoroquinolones; instead, the incidence was within expected seasonal variations for C. difficile-associated disease. Recognition of community-acquired cases and the use of culture may help to identify additional cases of C. difficile-associated disease. Early diagnosis and treatment of C. difficile cases may shorten the duration of hospital stays and reduce the number of outbreaks and readmissions, mortality, and other consequences of C. difficile infection.
Similar articles
- Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006.
Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Kim J, et al. Pediatrics. 2008 Dec;122(6):1266-70. doi: 10.1542/peds.2008-0469. Pediatrics. 2008. PMID: 19047244 - Epidemiology and risk factors for Clostridium difficile infection in children.
Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, Gidengil CA, Lee GM. Sandora TJ, et al. Pediatr Infect Dis J. 2011 Jul;30(7):580-4. doi: 10.1097/INF.0b013e31820bfb29. Pediatr Infect Dis J. 2011. PMID: 21233782 - A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.
Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, Thompson A, Jensen B, Wiggs L, Bessette J, Martin J, Clukey J, Gensheimer K, Killgore G, McDonald LC. Kazakova SV, et al. Arch Intern Med. 2006 Dec 11-25;166(22):2518-24. doi: 10.1001/archinte.166.22.2518. Arch Intern Med. 2006. PMID: 17159019 - Clostridium difficile-associated diarrhea: resurgence with a vengeance.
Oldfield EC 3rd. Oldfield EC 3rd. Rev Gastroenterol Disord. 2006 Spring;6(2):79-96. Rev Gastroenterol Disord. 2006. PMID: 16699477 Review.
Cited by
- Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.
Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. Aldape MJ, et al. J Med Microbiol. 2013 May;62(Pt 5):741-747. doi: 10.1099/jmm.0.056218-0. Epub 2013 Feb 21. J Med Microbiol. 2013. PMID: 23429695 Free PMC article. - Association of Single Nucleotide Polymorphisms in Nucleotide-Binding Domain Leucine-Rich Repeat Protein 1 with Clostridioides difficile Colonization or Infection.
Tsai BY, Tsai PJ, Lee CC, Chiu CW, Lai YH, Lee JC, Ko WC, Hung YP. Tsai BY, et al. Infect Drug Resist. 2023 Jan 24;16:413-421. doi: 10.2147/IDR.S392510. eCollection 2023. Infect Drug Resist. 2023. PMID: 36718463 Free PMC article. - Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.
Bloomfield LE, Riley TV. Bloomfield LE, et al. Infect Dis Ther. 2016 Sep;5(3):231-51. doi: 10.1007/s40121-016-0117-y. Epub 2016 Jul 1. Infect Dis Ther. 2016. PMID: 27370914 Free PMC article. Review. - Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.
McFarland LV. McFarland LV. World J Gastroenterol. 2010 May 14;16(18):2202-22. doi: 10.3748/wjg.v16.i18.2202. World J Gastroenterol. 2010. PMID: 20458757 Free PMC article. Review. - Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection.
Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Dial S, et al. CMAJ. 2008 Oct 7;179(8):767-72. doi: 10.1503/cmaj.071812. CMAJ. 2008. PMID: 18838451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical